{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T16:34:46Z","timestamp":1793896486381,"version":"4.8.0"},"reference-count":30,"publisher":"American Society of Hematology","issue":"7","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,4,8]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Venetoclax plus hypomethylating agents are considered standard of care for patients with acute myeloid leukemia (AML) judged ineligible for intensive chemotherapy (IC). Real-world studies complement clinical trials, because patterns of patient selection, treatment exposure, and postremission management may vary. This prospective observational multicenter study included 209 newly diagnosed IC-ineligible patients with a median age 75\u00a0years (interquartile range, 71-81 years). A high proportion of patients had secondary AML (53.7%), adverse-risk disease (35.3%), and complex karyotype (15.5%). At a median follow-up of 22.5\u00a0months (range, 0.1-43), median overall survival (mOS) was 11.7\u00a0months (95% confidence interval [CI], 9.9,15.4). Composite complete remission was achieved in 65.2% (CR, 44.4%; CR with incomplete hematologic recovery, 20.8%). Of responding patients, 21.1% underwent stem cell transplantation. When stratified based on VIALE-A original eligibility criteria, mOS was 17.8\u00a0months for patients meeting eligibility criteria and 10.7\u00a0months for patients who did not (P\u00a0=\u00a0.027). AML ontogeny (P\u00a0=\u00a0.024), reduced kidney function (P\u00a0=\u00a0.001), Charlson Comorbidity Index (CCI; P\u00a0=\u00a0.0017), European LeukemiaNET (ELN) risk (P\u00a0=\u00a0.01), and body mass index (P\u00a0=\u00a0.0298) were significantly associated with OS. Multivariant Cox regression analysis confirmed independent association of OS with AML ontogeny (P\u00a0=\u00a0.012), CCI (P\u00a0=\u00a0.033), and ELN risk (P\u00a0=\u00a0.019). Patients enrolled in the latter half of the study period demonstrated improved OS than those enrolled earlier (P\u00a0=\u00a0.026). This prospective observational study highlights outcomes of patient subgroups, including those excluded from registration trials. This trial was registered at www.clinicaltrials.gov as #NCT03987958.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024014014","type":"journal-article","created":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T15:02:46Z","timestamp":1733410966000},"page":"1544-1554","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":16,"title":["Trial eligibility, treatment patterns, and outcome for venetoclax-based therapy in AML: a prospective cohort study"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8662-0707","authenticated-orcid":false,"given":"Ofir","family":"Wolach","sequence":"first","affiliation":[{"name":"1Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Beilinson Hospital, Petach Tikva, Israel"},{"name":"2School of Medicine, Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itai","family":"Levi","sequence":"additional","affiliation":[{"name":"3Hematology Institute, Soroka Medical Center, Beer-sheba, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7341-2167","authenticated-orcid":false,"given":"Boaz","family":"Nachmias","sequence":"additional","affiliation":[{"name":"4Department of Hematology, Hadassah Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigal","family":"Tavor","sequence":"additional","affiliation":[{"name":"5Department of Hematology, Assuta Medical Center, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Amitai","sequence":"additional","affiliation":[{"name":"2School of Medicine, Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel"},{"name":"6Hematology Division, Chaim Sheba Medical Center, Ramat Gan, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5521-1337","authenticated-orcid":false,"given":"Yishai","family":"Ofran","sequence":"additional","affiliation":[{"name":"7The Hematology and Bone Marrow Transplantation Department, The Eisenberg Research and Development Authority, Shaare Zedek Medical Center, The Hebrew University of Jerusalem, Jerusalem, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1722-4807","authenticated-orcid":false,"given":"Chezi","family":"Ganzel","sequence":"additional","affiliation":[{"name":"7The Hematology and Bone Marrow Transplantation Department, The Eisenberg Research and Development Authority, Shaare Zedek Medical Center, The Hebrew University of Jerusalem, Jerusalem, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsila","family":"Zuckerman","sequence":"additional","affiliation":[{"name":"8Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel"},{"name":"9Bruce Rappaport Faculty of Medicine, Technion, Israel Institute of Technology, Haifa, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doaa","family":"Okasha","sequence":"additional","affiliation":[{"name":"10Department of Hematology, Ha\u2019Emek Medical Center, Afula, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilana","family":"Hellmann","sequence":"additional","affiliation":[{"name":"11Department of Hematology, Meir Medical Center, Kfar Saba, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamar","family":"Tadmor","sequence":"additional","affiliation":[{"name":"9Bruce Rappaport Faculty of Medicine, Technion, Israel Institute of Technology, Haifa, Israel"},{"name":"12Hematology Unit, Bnai Zion Medical Center, Haifa, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najib","family":"Dally","sequence":"additional","affiliation":[{"name":"13Hematology Unit, Ziv Medical Center and the Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Canaani","sequence":"additional","affiliation":[{"name":"14Weill Medical College of Cornell University, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Galia","family":"Stemer","sequence":"additional","affiliation":[{"name":"15Hematology Unit, Galilee Medical Center, Nahariya and the Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moshe","family":"Grunspan","sequence":"additional","affiliation":[{"name":"16AbbVie Inc, Hod-Hasharon, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adi Jacob","family":"Berger","sequence":"additional","affiliation":[{"name":"16AbbVie Inc, Hod-Hasharon, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neta","family":"Frankel","sequence":"additional","affiliation":[{"name":"16AbbVie Inc, Hod-Hasharon, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenia","family":"Berelovich","sequence":"additional","affiliation":[{"name":"16AbbVie Inc, Hod-Hasharon, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Bleterman","sequence":"additional","affiliation":[{"name":"16AbbVie Inc, Hod-Hasharon, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moran","family":"Barak","sequence":"additional","affiliation":[{"name":"16AbbVie Inc, Hod-Hasharon, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raanan","family":"Cohen","sequence":"additional","affiliation":[{"name":"16AbbVie Inc, Hod-Hasharon, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yakir","family":"Moshe","sequence":"additional","affiliation":[{"name":"17Department of Hematology and Bone Marrow Transplantation Unit, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,3,27]]},"reference":[{"issue":"12","key":"2025040814521745200_bib1","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"7","key":"2025040814521745200_bib2","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"2025040814521745200_bib3","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1200\/JCO.21.01546","article-title":"Measurable residual disease response and prognosis in treatment-na\u00efve acute myeloid leukemia with venetoclax and azacitidine","volume":"40","author":"Pratz","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"2025040814521745200_bib4","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/ajh.27246","article-title":"Long-term follow-up of VIALE-A: venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia","volume":"99","author":"Pratz","year":"2024","journal-title":"Am J Hematol"},{"issue":"44","key":"2025040814521745200_bib5","doi-asserted-by":"crossref","first-page":"72044","DOI":"10.18632\/oncotarget.12495","article-title":"Improved outcome in acute myeloid leukemia patients enrolled in clinical trials: a national population-based cohort study of Danish intensive chemotherapy patients","volume":"7","author":"\u00d8stg\u00e5rd","year":"2016","journal-title":"Oncotarget"},{"key":"2025040814521745200_bib6","doi-asserted-by":"crossref","first-page":"100913","DOI":"10.1016\/j.blre.2021.100913","article-title":"Reality check: real-world evidence to support therapeutic development in hematologic malignancies","volume":"53","author":"Derman","year":"2022","journal-title":"Blood Rev"},{"issue":"4","key":"2025040814521745200_bib7","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1002\/ajh.27231","article-title":"Clinical outcomes of hypomethylating agents plus venetoclax as frontline treatment in patients 75 years and older with acute myeloid leukemia: real-world data from eight US academic centers","volume":"99","author":"Abaza","year":"2024","journal-title":"Am J Hematol"},{"issue":"7","key":"2025040814521745200_bib8","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/ajh.26190","article-title":"Venetoclax combinations induce high response rates in newly diagnosed acute myeloid leukemia patients ineligible for intensive chemotherapy in routine practice","volume":"96","author":"Apel","year":"2021","journal-title":"Am J Hematol"},{"key":"2025040814521745200_bib9","doi-asserted-by":"crossref","first-page":"106803","DOI":"10.1016\/j.leukres.2022.106803","article-title":"Venetoclax in combination with hypomethylating agents in previously untreated patients with acute myeloid leukemia ineligible for intensive treatment: a real-life multicenter experience","volume":"114","author":"De Bellis","year":"2022","journal-title":"Leuk Res"},{"issue":"suppl 1","key":"2025040814521745200_bib10","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1182\/blood-2023-178505","article-title":"Real world outcome of unfit patients with acute myeloid leukemia treated with the combination venetoclax plus hypomethylating agents in the Gimema AML2320 observational trial","volume":"142","author":"Venditti","year":"2023","journal-title":"Blood"},{"issue":"20","key":"2025040814521745200_bib11","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1182\/bloodadvances.2019000243","article-title":"Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia","volume":"3","author":"Winters","year":"2019","journal-title":"Blood Adv"},{"issue":"20","key":"2025040814521745200_bib12","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"4","key":"2025040814521745200_bib13","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"issue":"8","key":"2025040814521745200_bib14","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1002\/ajh.24410","article-title":"Allogeneic transplantation is not superior to chemotherapy in most patients over 40 years of age with Philadelphia-negative acute lymphoblastic leukemia in first remission","volume":"91","author":"Wolach","year":"2016","journal-title":"Am J Hematol"},{"issue":"1","key":"2025040814521745200_bib15","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2141.2004.05094.x","article-title":"Tumour lysis syndrome: new therapeutic strategies and classification","volume":"127","author":"Cairo","year":"2004","journal-title":"Br J Haematol"},{"issue":"4","key":"2025040814521745200_bib16","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1080\/10428194.2023.2173523","article-title":"Venetoclax in combination with hypomethylating agent for the treatment of advanced myeloproliferative neoplasms and acute myeloid leukemia with extramedullary disease","volume":"64","author":"Sanber","year":"2023","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"2025040814521745200_bib17","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1002\/ajh.26186","article-title":"Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: a multicenter series of 32\u00a0consecutive cases","volume":"96","author":"Gangat","year":"2021","journal-title":"Am J Hematol"},{"issue":"suppl 1","key":"2025040814521745200_bib18","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1182\/blood-2022-169509","article-title":"ELN risk stratification is not predictive of outcomes for treatment-na\u00efve patients with acute myeloid leukemia treated with venetoclax and azacitidine","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"24","key":"2025040814521745200_bib19","doi-asserted-by":"crossref","first-page":"5272","DOI":"10.1158\/1078-0432.CCR-22-1183","article-title":"Outcomes in patients with poor-risk cytogenetics with or without TP53 mutations treated with venetoclax and azacitidine","volume":"28","author":"Pollyea","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"7","key":"2025040814521745200_bib20","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1038\/s41416-023-02362-3","article-title":"Impact of BMI on patient outcome in acute myeloid leukaemia patients receiving intensive induction therapy: a real-world registry experience","volume":"129","author":"En\u00dfle","year":"2023","journal-title":"Br J Cancer"},{"issue":"18","key":"2025040814521745200_bib21","doi-asserted-by":"crossref","first-page":"5234","DOI":"10.1182\/bloodadvances.2023009976","article-title":"Effect of BMI on toxicities and survival among adolescents and young adults treated on DFCI Consortium ALL trials","volume":"7","author":"Shimony","year":"2023","journal-title":"Blood Adv"},{"issue":"7","key":"2025040814521745200_bib22","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.3390\/nu15071780","article-title":"The obesity paradox and mortality in older adults: a systematic review","volume":"15","author":"Dram\u00e9","year":"2023","journal-title":"Nutrients"},{"issue":"17","key":"2025040814521745200_bib23","doi-asserted-by":"crossref","first-page":"17914","DOI":"10.1002\/cam4.6430","article-title":"Post-remission cytopenia management in patients with AML treated with venetoclax in combination with hypomethylating agents: pre-versus post-VIALE-A real-world experience from a predominantly US community setting","volume":"12","author":"Vachhani","year":"2023","journal-title":"Cancer Med"},{"issue":"2","key":"2025040814521745200_bib24","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s00277-021-04693-8","article-title":"Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first complete remission after 5-azacitidine and venetoclax: a multicenter retrospective study","volume":"101","author":"Pasvolsky","year":"2022","journal-title":"Ann Hematol"},{"issue":"10","key":"2025040814521745200_bib25","doi-asserted-by":"crossref","first-page":"694.e1","DOI":"10.1016\/j.jtct.2022.07.022","article-title":"Outcomes are similar after allogeneic hematopoietic stem cell transplant for newly diagnosed acute myeloid leukemia patients who received venetoclax\u00a0+ azacitidine versus intensive chemotherapy","volume":"28","author":"Winters","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"2","key":"2025040814521745200_bib26","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41409-021-01476-7","article-title":"Venetoclax and azacitidine followed by allogeneic transplant results in excellent outcomes and may improve outcomes versus maintenance therapy among newly diagnosed AML patients older than 60","volume":"57","author":"Pollyea","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"suppl 1","key":"2025040814521745200_bib27","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1182\/blood-2020-143002","article-title":"Hypomethylating agents in combination with venetoclax as a bridge to allogeneic transplant in acute myeloid leukemia","volume":"136","author":"Kennedy","year":"2020","journal-title":"Blood"},{"issue":"6","key":"2025040814521745200_bib29","doi-asserted-by":"crossref","first-page":"E191","DOI":"10.1002\/ajh.26524","article-title":"Outcomes of allogeneic transplantation after hypomethylating agents with venetoclax in acute myeloid leukemia","volume":"97","author":"Kennedy","year":"2022","journal-title":"Am J Hematol"},{"issue":"suppl 1","key":"2025040814521745200_bib30","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1182\/blood-2021-150815","article-title":"Outcomes and predictors of relapse with use of hypomethylating agents in combination with venetoclax prior to allogeneic transplant in acute myeloid leukemia","volume":"138","author":"Nizamuddin","year":"2021","journal-title":"Blood"},{"issue":"1","key":"2025040814521745200_bib31","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1182\/hematology.2023000428","article-title":"The approach of HMA plus VEN with or without BMT for all patients with AML","volume":"2023","author":"Male","year":"2023","journal-title":"Hematology Am Soc Hematol Educ Program"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/7\/1544\/2362780\/blooda_adv-2024-014014-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/7\/1544\/2362780\/blooda_adv-2024-014014-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T11:18:05Z","timestamp":1744111085000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/7\/1544\/534344\/Trial-eligibility-treatment-patterns-and-outcome"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,27]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,4,8]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024014014","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,27]]}}}